Une étude pour investiguer la pharmacocinétique et la sécurité du Risdiplam chez les nourrissons atteints d'atrophie musculaire spinale
This research is investigating a medicine called risdiplam for very young babies diagnosed with spinal muscular atrophy (SMA). SMA is a genetic condition that affects muscles. The study wants to find out how risdiplam moves through the bodies of infants under 20 days old at their first dose, and whether it is safe for them. By carefully studying these things, researchers hope to learn more about how to best treat SMA in newborns. This could lead to better care options for families facing this condition, helping to improve the health and well-being of these babies.
En un coup d'œil
De quoi parle cette étude ?
This research study is focused on a medicine called risdiplam, which is being investigated for spinal muscular atrophy (SMA). SMA is a rare genetic condition that affects the nerves that control muscle movement, leading to muscle weakness and wasting. This particular study is looking at how risdiplam works in the bodies of newborn babies with SMA.
The main goals are to understand how the medicine is absorbed, distributed, processed, and removed by a baby's body (this is called pharmacokinetics), and to check if it's safe for them. The study specifically includes babies who are under 20 days old when they receive their first dose of the medicine. By gathering this important information, doctors can learn more about how to use risdiplam effectively and safely for the very youngest patients.
Finding out how medicines work in newborns is really important because their bodies are different from older children and adults. This research aims to provide valuable insights that could help improve future treatments and care for infants born with SMA, giving them the best possible start in life.
Points clés
- This study is for newborn babies (under 20 days old) with SMA.
- It's looking at a medicine called risdiplam to understand its safety and how it works in infants.
- Participation involves regular check-ups and monitoring by medical staff.
- The goal is to improve care for babies with SMA.
- You can withdraw your baby from the study at any time.
Qui peut être éligible ?
This study is looking for newborn babies who are less than 20 days old at the time of their first dose of medication. They must have a confirmed diagnosis of spinal muscular atrophy (SMA) through genetic testing or newborn screening. Babies should have been born at 37 weeks gestation or later and be recovering well from any recent illnesses.
There are also some things that would mean a baby couldn't join the study. For example, if they show severe signs of SMA Type 0, or if they have certain heart problems. Also, if a baby is currently taking or has recently taken certain other medications, they might not be able to participate.
Parents or caregivers will need to be open to the possibility of using feeding tubes (like a nasogastric tube or gastrostomy tube) if the doctors recommend it to make sure the baby gets enough food, water, and medicine during the study.
Cet étude pourrait-elle vous convenir ?
Répondez à ces questions rapides pour voir si vous êtes éligible. Ceci est un guide uniquement — l'équipe de recherche prend la décision finale.
- Is my baby under 20 days old?
- Has my baby been diagnosed with SMA through testing?
- Was my baby born at 37 weeks gestation or later?
- Is my baby currently well enough to potentially join a study?
- Am I open to the possibility of a feeding tube for my baby if recommended by doctors?
En quoi consiste la participation ?
Taking part in this study would involve your baby receiving the study medicine, risdiplam. Doctors and nurses would regularly check your baby's health, including taking blood samples to understand how the medicine is affecting them and ensuring their safety. They would also monitor your baby's development and any changes related to their SMA.
You would have regular visits to the clinic for these assessments. The study team would explain the schedule of visits and what each one involves. Throughout the study, medical staff would be closely observing your baby and providing care. The total duration of participation in this study would be explained to you before you make any decisions.
Risques et avantages potentiels
Locations (13)
- Ann and Robert H. Lurie Children Hospital of ChicagoCode postal vérifiéChicago, États-Unis· Recrutement
- University Of MichiganCode postal vérifiéAnn Arbor, États-Unis· Recrutement
- Clinic for Special Children.Code postal vérifiéGordonville, United States· Recrutement
- Hopital Universitaire des Enfants Reine FabiolaCode postal vérifiéBruxelles, Belgique· Recrutement
- CHR CitadelleCode postal vérifiéLiège, Belgium· Recrutement
- Children'S Hospital of Eastern OntarioCode postal vérifiéOttawa, Canada· Recrutement
- Universitatsklinikum EssenCode postal vérifiéEssen, Allemagne· Recrutement
- Fondazione Serena Onlus - CENTRO CLINICO NEMOVille uniquementMilano, Italy· Recrutement
- Fondazione Policlinico Univeristario A. GemelliVille uniquementROMA, Italy· Recrutement
- UMC UtrechtCode postal vérifiéUtrecht, Pays-Bas· Recrutement
- OUS (Oslo University Hospital), RikshospitaletCode postal vérifiéOslo, Norway· Recrutement
- Uniwersyteckie Centrum KliniczneCode postal vérifiéGdansk, Poland· Recrutement
Questions fréquentes
What is spinal muscular atrophy (SMA)?
SMA is a genetic condition that causes muscle weakness. It affects the nerve cells that control movement, making muscles weaker over time.
What is risdiplam?
Risdiplam is a medicine being tested for SMA. It aims to help the body produce more of a protein that is needed for healthy nerves and muscles.
Why are you only studying very young babies?
Studying very young babies helps us understand how the medicine works in their developing bodies, which is different from older children or adults. This information is crucial for safe and effective treatment early on.
What does 'pharmacokinetics' mean?
'Pharmacokinetics' is a medical term that means how a medicine moves through the body – how it's absorbed, where it goes, how it's changed, and how it leaves the body.
Will my baby get special care if they join the study?
Yes, your baby will receive close medical attention and monitoring from the study team throughout their participation.
Comment en savoir plus
Reference Study ID Number: BN44619 https://forpatients.roche.com/
Parlez toujours à votre médecin généraliste ou spécialiste avant de décider de participer à une étude.
Intéressé à participer ?
Discussion
Discussion communautaire
Propulsé par notre forum à community.patient.info. Veuillez être respectueux — ceci n'est pas un avis médical.